NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Genprex Inc., a clinical stage gene therapy company developing a new approach to treating cancer.
NNW’s Stuart Smith introduces Genprex CEO and Chairman Rodney Varner, JD, for a compelling discussion on the company’s initial product candidate, Oncoprex(TM), an immunogene therapy for non-small cell lung cancer (NSCLC).
The interview can be heard at http://nnw.fm/QUUu0
The American Cancer Society reports that NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer. More people die of the disease each year than of colon, breast and prostate cancers combined. Survival for late-stage lung cancer has not improved significantly in the past 25 years, despite radical advances in drug development and novel therapeutic standards. Genprex technologies are being developed to overcome genomic limitations, which are inherent in targeted therapies, to provide new treatment solutions to large cancer populations and improve outcomes.
“Our approach is to deliver a tumor suppressor gene to tumor cells by encapsulating the gene in a DOTAP:cholesterol nanoparticle which is then injected intravenously and targets tumor cells,” Varner explains. “Our technology is currently in a phase II clinical trial for non-small cell lung cancer being conducted at the M.D. Anderson Cancer Center (University of Texas) in Houston.”
Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Preclinical and clinical data indicate that Oncoprex may be effective alone or in combination with targeted small molecule therapies and immunotherapies.
Varner says he is enthusiastic about the important work being accomplished at Genprex, which was formed in 2009. The company continues to add industry-leading members to its board of directors and scientific advisory board which includes Nobel Prize laureate Dr. James E. Rothman, PhD, who serves as a strategic advisor.
“I’m very proud of our board and scientific advisors,” Varner says. “I think it would be hard to find a more distinguished group.”
Genprex plans to continue its current phase II clinical trial at the Texas cancer center and expects to advance additional clinical trials at other sites. The company’s long-term goal is to continue to develop its immunogene therapies and add additional products to its drug pipeline that attack not only lung cancer but many other cancers, Varner concludes.
About Genprex Inc.
Genprex Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation. For more information, visit: www.NetworkNewsAudio.com
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex on cancer. Risks and uncertainties associated with Genprex and its lead product candidate Oncoprex are described more fully under the caption "Risk Factors" and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
GNPX investor relations
(877) 774-GNPX (4679) ext. #2
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3